Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 4
R&D Momentum
94/100
Pipeline Velocity
73/100
Trial Completion Rate
83/100
Pipeline Concentration
20/100
Pipeline Freshness
76/100
Strategic Signals
Activity
Last 14 days
Aim 3 - Precision Coordination of Therapeutic and Prophylactic Antibiotics to Reduce Infection, Toxicity, and Emergence of Resistance Following Acute Abdominal Surgery
Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury
Investigating Near-Threshold Perception During Anesthetic Sedation
Pilot Randomized Controlled Trial of the RENEW Intervention for Axial Spondyloarthritis
Leveraging Virtual Care Strategies to Improve Access and Treatment for Individuals With Alcohol Use Disorders (AUD)
Investigating Resistance Training for Vascular Function and Quality of Life in Perimenopausal Women
Pilot Project 1. Feasibility Pilot of a JITAI to Reduce Cannabis Use Among Emerging Adults
Clinical Characterization of Burst Spinal Cord Stimulation for Chronic Pain Management
Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)